An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC

NCT05327582 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

65

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer
Biliary Tract Cancer

Interventions

DRUG: Durvalumab
DRUG: Lenvatinib
DRUG: Nab paclitaxel

Sponsor

Chinese PLA General Hospital